No Data
No Data
HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $15 Price Target
Biora Therapeutics Analyst Ratings
Biora Therapeutics Buy Rating Confirmed by Positive Phase 1 Trial Outcomes and NaviCap Technology Potential
Biora Therapeutics Advances Ulcerative Colitis Treatment With BT-600 Trial Success
Biora Therapeutics Announces Presentation Of Supplemental Data From Phase 1 BT-600 Trial; Says 'Pharmacokinetic and Tissue Data Confirm NaviCap Platform Delivers Topically Through the Entire Colon, With Lower Systemic Concentrations, as Desired'
Express News | Biora Therapeutics Announces Supplemental Data From Phase 1 Clinical Trial of BT-600 as Presented at Kol Event
No Data